Skip to main content
Fig. 3 | Cancer Nanotechnology

Fig. 3

From: Enhanced cancer immunotherapy through synergistic ferroptosis and immune checkpoint blockade using cell membrane-coated nanoparticles

Fig. 3

PD-1@RSL3 NPs boosted tumor cell ferroptosis in breast cancer cells. a Western blot analysis confirmed the downregulated GPX4 expression in 4T1 cells treated with PD-1@RSL3 NPs for 48 h. b, c Flow cytometry analysis and the normalized ratio of lipid ROS production in 4T1 cells using a fluorescence probe C11 BODIPY®581/591. d Lipid peroxidation analysis in 4T1 cells treated with different formulations via MDA assay. e CLSM analysis of lipid peroxidation (green) using C11 BODIPY®581/591 in 4T1 cells. Scale bar: 20 μm. The concentrations of RSL3 and IFN-γ used in a–e were 5 μM and 100 ng/ml, respectively

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us